Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Acral Lentiginous Melanoma. According to GlobalData, Phase I drugs for Acral Lentiginous Melanoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Exlinkibart LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Exlinkibart overview
Exlinkibart (LVGN-6051) is under development for the treatment of advanced or metastatic malignancy including lung cancer, melanoma, recurrent head and neck cancer squamous cell carcinoma, oral cavity, oropharynx cancer, acral melanoma, hypopharyngeal cancer, laryngeal cancer, B-cell non-Hodgkin’s lymphoma and non-small cell lung cancer, pancreatic cancer, gastrointestinal tract cancer and lymphoma. It is a humanized monoclonal antibody that acts by targeting CD137 and FCGR2B. It is administered through intravenous infusion. The drug candidate is developed based on cross-link antibody (xLinkAb) platform.
It was also under development for the treatment of castration resistant prostate cancer.
Lyvgen Biopharma overview
Lyvgen Biopharma, is a cancer immunotherapy service provider. The company is headquartered in China.
For a complete picture of Exlinkibart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
